Literature DB >> 26010208

Paraneoplastic neuromyelitis optica spectrum disorders: three new cases and a review of the literature.

Gang Cai1, Dian He1, Lan Chu1, Qingqing Dai1, Zhu Xu1, Yifan Zhang1.   

Abstract

Neuromyelitis optica spectrum disorders (NMOSD) occasionally develop in patients with tumor in relation to aquaporin-4 IgG (AQP4-IgG), representing a new paraneoplastic phenomenon. We reported three patients with paraneoplastic NMOSD and provided a comprehensive review of the literature. A total of 34 cases with paraneoplastic NMOSD were identified from our own case database (n = 3) and the previous literature (n = 31). The median age at NMOSD-related symptom onset was 50.5 years, and 91% of the cases were female. 11 (32%) cases had breast carcinoma. In 15 (44%) cases, NMOSD-related symptoms preceded tumor detection [median, 4 (range 1-180) months], and in 19 (56%) cases, symptoms followed tumor detection [median, 12 (range 3-180) months]. 5/14 (36%) cases had hiccups and vomiting as the initial symptoms, with the involvement of medulla oblongata. In 10/14 (71%) cases, cervical spinal cord was involved. In contrast to idiopathic NMO, NMOSD is more likely to be paraneoplastic than in patients aged over 50 years at the onset of symptoms, especially for female patients. Breast carcinoma is the most common tumor associated with paraneoplastic NMOSD, accounting for nearly a third of all types of tumors. Paraneoplastic NMOSD usually involves medulla oblongata and cervical spinal cord. We recommend adding AQP4-IgG as an onconeural antibody, but its clinical utility warrants further investigations.

Entities:  

Keywords:  AQP4-IgG; NMO-IgG; longitudinally extensive transverse myelitis; neuromyelitis optica spectrum disorders; optic neuritis; paraneoplastic syndrome

Mesh:

Year:  2015        PMID: 26010208     DOI: 10.3109/00207454.2015.1054481

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  9 in total

1.  Neuromyelitis optica spectrum disorder and adenocarcinoma of ovary: a novel association.

Authors:  Julie Sachdeva; Ramandeep Bansal; Aastha Takkar; Rajveer Singh
Journal:  BMJ Case Rep       Date:  2019-04-24

Review 2.  Magnetic resonance imaging in immune-mediated myelopathies.

Authors:  M J Wendebourg; S Nagy; T Derfuss; K Parmar; R Schlaeger
Journal:  J Neurol       Date:  2019-01-29       Impact factor: 4.849

3.  Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.

Authors:  Maria Sepúlveda; Nuria Sola-Valls; Domingo Escudero; Bojan Rojc; Manuel Barón; Luis Hernández-Echebarría; Begoña Gómez; Josep Dalmau; Albert Saiz; Francesc Graus
Journal:  Mult Scler       Date:  2017-09-18       Impact factor: 6.312

4.  SLE presenting as demyelinative autoimmune visual loss.

Authors:  Ami Schattner; Shilo Voichanski; Livnat Uliel
Journal:  BMJ Case Rep       Date:  2018-03-05

5.  Paraneoplastic neuromyelitis optica spectrum disorders: a case series.

Authors:  Eleonora Virgilio; Domizia Vecchio; Marco Vercellino; Paola Naldi; Fabiana Tesser; Roberto Cantello; Paola Cavalla; Cristoforo Comi
Journal:  Neurol Sci       Date:  2021-01-28       Impact factor: 3.307

6.  Screening for onconeural antibodies in neuromyelitis optica spectrum disorders.

Authors:  Benjamin Berger; Tilman Hottenrott; Sebastian Rauer; Oliver Stich
Journal:  BMC Neurol       Date:  2017-01-10       Impact factor: 2.474

Review 7.  Autophagy in white matter disorders of the CNS: mechanisms and therapeutic opportunities.

Authors:  Erik Nutma; Manuel C Marzin; Saskia Agm Cillessen; Sandra Amor
Journal:  J Pathol       Date:  2020-12-04       Impact factor: 9.883

Review 8.  AQP4-IgG positive paraneoplastic NMOSD: A case report and review.

Authors:  Manqiu Ding; Yue Lang; Li Cui
Journal:  Brain Behav       Date:  2021-09-14       Impact factor: 2.708

9.  Paraneoplastic Neuromyelitis Optica Spectrum Disorder Associated With Lung Adenocarcinoma: A Case Report.

Authors:  Carlo Maiorca; Federica Moret; Valentina Martines; Daniele Tramontano; Maria Alessia Papassifachis; Simone Bini; Claudia Caramazza; Mario Fontana; Piernatale Lucia; Maurizio Inghilleri
Journal:  Front Med (Lausanne)       Date:  2022-01-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.